Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Cuneo – page 4

81 clinical trials in Cuneo, Italy. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Cuneo at a glance
81
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

81 trials in Cuneo

Open in trial search

Colon cancer stage III+1

Not yet recruiting

Study on Post-Surgery Treatment for Colon Cancer Patients Using Trifluridine, Irinotecan, and Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Fondazione GONO G.I.

IgA nephropathy

Not yet recruiting

Study on Corticosteroids, Dapagliflozin, and Drug Combination for Proteinuria in IgA Nephropathy Patients with Active or Chronic Kidney Lesions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Fondazione Schena Centro Europeo Della Ricerca Sulle Malattie Renali

Neoplasm

Not recruiting

Study on the Safety and Tolerability of TransCon IL-2 β/γ, Pembrolizumab, and Chemotherapy in Adults with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ACP-017
  • Sponsor:Ascendis Pharma Oncology Division A/S

Chronic kidney disease

Not recruiting

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Plasma cell myeloma refractory

Not recruiting

A Phase 2 Study of JNJ-79635322 in Patients with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
  • Sponsor:Janssen Cilag International

Breast cancer

Not recruiting

Study on Chemotherapy and Aromatase Inhibitors (Exemestane, Letrozole, Anastrozole) for Post-Menopausal Patients with Early Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:IRCCS Ospedale Policlinico San Martino

Plasma cell myeloma

Not recruiting

Study on Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Universita' Degli Studi Di Torino

Follicular lymphoma

Not recruiting

Study on Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma Not Eligible for Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Fondazione Italiana Linfomi Ets

Follicular lymphoma

Not recruiting

Study Comparing Shortened vs Standard Chemotherapy with Rituximab for Initial Treatment of High Tumor Burden Follicular Lymphoma in Newly Diagnosed Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Fondazione Italiana Linfomi Ets

Acute lymphocytic leukaemia

Not recruiting

Study of inotuzumab ozogamicin and drug combination in adult patients with B-cell Acute Lymphoblastic Leukemia who have minimal residual disease before stem cell transplantation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Triple negative breast cancer

Not recruiting

Study on Avelumab for Patients with High-Risk Triple Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Universita Degli Studi Di Padova

Relapsing multiple sclerosis

Not recruiting

Study on Fenebrutinib and Teriflunomide for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Fenebrutinib
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Cuneo

What the registry says about research in the country

01 Hematologic Oncology

Groundbreaking trials focusing on Acute Myeloid Leukemia (AML) and various lymphomas, testing innovative combination therapies and transplantation approaches.

  • Leukemia treatments
  • Stem cell transplantation
  • Novel drug combinations

Studies evaluating targeted therapies for Multiple Myeloma and Chronic Lymphocytic Leukemia.

02 Solid Tumors

Research examining innovative treatments for breast cancer, including trials for triple-negative and hormone-responsive subtypes.

  • Immunotherapy combinations
  • Targeted therapies
  • Maintenance treatments

Advanced studies in ovarian cancer and lung cancer, exploring novel therapeutic approaches.

03 Emerging Therapeutics

Investigating immunotherapy approaches across multiple cancer types, with focus on combination strategies.

  • Antibody therapies
  • Targeted molecules
  • Maintenance protocols

Evaluation of novel drug combinations and treatment sequences for optimal patient outcomes.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.